ER
Therapeutic Areas
Kamada Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Inhaled AAT (KMA-001) | Alpha-1 Antitrypsin Deficiency (AATD) with emphysema | Phase 3 |
| IV AAT | Graft-Versus-Host Disease (GvHD) | Phase 2 |
| Anti-Rabies IgG (KamRab) | Rabies Post-Exposure Prophylaxis | Marketed |
Leadership Team at Kamada
AL
Amir London
Chief Executive Officer
GN
Guy Neev
Chief Financial Officer
JB
Joshua Berkman
Senior VP, Corporate Communications & Investor Relations
NG
Nathalie Gordin
Senior VP, Global Human Resources
DE
Dr. Eran Schenker
Chief Medical Officer
RK
Roni Klapholz
Senior VP, Global Commercial Operations